How Does Cronos Group Inc (CRON) Stock Stack Up in the Healthcare Sector?

Friday, November 22, 2019 3:01 PM | InvestorsObserver Analysts

The 37 rating InvestorsObserver gives to Cronos Group Inc (CRON) stock puts it near the top of the Healthcare sector.

In addition to scoring higher than 42 percent of stocks in the Healthcare sector, CRON’s 37 overall rating means the stock scores better than 37 of all stocks.

Click Here to get the full Stock Score Report on Cronos Group Inc (CRON) Stock.

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cronos Group Inc Stock Today?

Cronos Group Inc (CRON) stock is down -7.66% while the S&P 500 is up 0.19% as of 3:00 PM on Friday, Nov 22. CRON is lower by -$0.58 from the previous closing price of $7.62 on volume of 10,089,510 shares. Over the past year the S&P 500 has gained 18.11% while CRON is lower by -20.09%. CRON lost -$0.02 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for CRON click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Is Twist Bioscience Corp (TWST) Stock About to Get Hot Tuesday?

Do Traders View Takeda Pharmaceutical Co Ltd (TAK) Stock's Current Trend Positively?

Should You Buy Quotient Ltd (QTNT) Stock After it Has Fallen 2.82% in a Week?

Where Will Citius Pharmaceuticals Inc (CTXR) Stock Go Next After It Is Down 0.95% in a Week?

Related Companies